Enterome Showcases EO2463 Trial Results at 2024 ASCO Meeting

Enterome, a biopharmaceutical company, is set to present clinical data from its Phase 1/2 trial of EO2463 at the 2024 ASCO Annual Meeting. EO2463 is a novel immunotherapy that targets specific B cell markers in indolent non-Hodgkin lymphoma (NHL). The study, known as SIDNEY (EONHL1-20), is an open-label, first-in-human trial that evaluates EO2463 both as a standalone treatment and in combination with lenalidomide and/or rituximab. It is designed to assess the safety, tolerability, and efficacy of this therapy in approximately 60 patients diagnosed with follicular lymphoma and marginal zone lymphoma.

EO2463 is a synthetic immunotherapy candidate that includes four OncoMimic™ peptides, which are non-self, microbial-derived peptides that mimic B lymphocyte-specific lineage markers. This unique approach aims to selectively target and destroy malignant B lymphocytes while minimizing harm to normal peripheral B cells. The therapy also includes a universal cancer peptide 2 (UCP2), which is a helper peptide for CD4+ epitopes.

Enterome's drug discovery platform is based on the analysis of gut bacterial proteins, which interact with the human body and provide new biological insights. The company's drug candidates are designed to modulate the immune system by mimicking specific antigens, hormones, or cytokines.

In addition to EO2463, Enterome has other drug candidates in its pipelines. EO2401 is in Phase 2 trials for glioblastoma and adrenal tumors, while EO4010 is in Phase 2 trials for indolent NHL and third-line colorectal cancer. The company is also developing EndoMimics™ peptides in collaboration with Nestlé Health Science for food allergies and inflammatory bowel disease, with the lead candidate, EB1010, expected to enter clinical development in 2024.

Enterome, headquartered in Paris, employs 70 people and has raised a significant amount of funding from life science investors and pharmaceutical partnerships. The company's innovative approach to immunotherapy and its ongoing clinical trials demonstrate its commitment to developing breakthrough treatments for cancer and immune diseases.